Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 11 of 38
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
NCT03743662
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
NCT03728972
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
NCT03693014
A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors
NCT03707340
Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship
NCT03674437
A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage
NCT03672019
Investigating the Impact of Proactive Palliative Care
NCT03667378
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
NCT03635892
Imaging With a PET Agent for Detection of Cancers of the Head and Neck
NCT03631017
Ixazomib Maintenance Study in Patients With AL Amyloidosis
NCT03618537
Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors
NCT03604302
Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
NCT03619083
A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
NCT03556332
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT03436654
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
NCT03574571
A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers
NCT03567642
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
NCT03531736
Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
NCT03523312
Overnight Fasting After Completion of Therapy: The OnFACT Study
NCT03523377
A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy
NCT03520491
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
NCT03484884
Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes
NCT03473795
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
NCT03465618
A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients
NCT03285152
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
NCT03410875
Exercise, Fitness and Tumor Profiling in Breast Cancer Patients
NCT03424915
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03414229
Treating Patients With Melanoma and ALK Alterations With Ensartinib
NCT03420508
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
NCT03315026
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
NCT03377387
A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors
NCT03432806
A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients
NCT03352765
BRCA Founder OutReach (BFOR) Study
NCT03351803
Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma
NCT03323463
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
NCT03315910
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
NCT03290950
Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer
NCT03289195
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03282344
Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)
NCT03269422
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
NCT03255577
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT03220477
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
NCT03220646
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
NCT03215095
Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination
NCT03209713
Understanding the Late Effects of Surviving a Pediatric Brain Tumor
NCT03208387
Exercise Exposure Data Collection in Patients Undergoing Tumor Molecular Profiling
NCT03208374
PSMA PET Imaging of Recurrent Prostate Cancer
NCT03204123
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
NCT03196518
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
NCT03189706
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.